AEterna Zentaris and Spectrum Pharmaceuticals announced that their experimental therapy for non-cancerous enlarged prostate improved symptoms in patients. After 12 weeks of dosing with Ozarelix, patients achieved a 47 percent higher evaluation score than patients taking a placebo. A late-stage trial is being planned. AEtner licensed Ozarelix back in 2004 for North America and India. Report